BioMarin Pharmaceutical Inc (BMRN): Price and Financial Metrics


BioMarin Pharmaceutical Inc (BMRN): $116.71

1.36 (+1.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BMRN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BMRN POWR Grades

  • BMRN scores best on the Growth dimension, with a Growth rank ahead of 99.08% of US stocks.
  • The strongest trend for BMRN is in Sentiment, which has been heading down over the past 179 days.
  • BMRN ranks lowest in Sentiment; there it ranks in the 37th percentile.

BMRN Stock Summary

  • With a price/earnings ratio of 255.48, BIOMARIN PHARMACEUTICAL INC P/E ratio is greater than that of about 98.03% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for BIOMARIN PHARMACEUTICAL INC is higher than 96.86% of stocks in our set with a positive cash flow.
  • Over the past twelve months, BMRN has reported earnings growth of -456.8%, putting it ahead of just 3.59% of US stocks in our set.
  • Stocks that are quantitatively similar to BMRN, based on their financial statements, market capitalization, and price volatility, are AGYS, NBIX, FSLR, PINS, and AXON.
  • Visit BMRN's SEC page to see the company's official filings. To visit the company's web site, go to www.biomarin.com.

BMRN Valuation Summary

  • BMRN's EV/EBIT ratio is 185.3; this is 1725.62% higher than that of the median Healthcare stock.
  • BMRN's EV/EBIT ratio has moved up 191.1 over the prior 243 months.

Below are key valuation metrics over time for BMRN.

Stock Date P/S P/B P/E EV/EBIT
BMRN 2023-01-30 10.6 4.7 254.0 185.3
BMRN 2023-01-27 10.9 4.8 259.7 189.4
BMRN 2023-01-26 10.8 4.8 259.1 189.0
BMRN 2023-01-25 10.7 4.7 257.0 187.4
BMRN 2023-01-24 10.5 4.6 252.1 183.9
BMRN 2023-01-23 10.3 4.5 246.8 180.2

BMRN Growth Metrics

    Its year over year net income to common stockholders growth rate is now at -95.05%.
  • The 4 year price growth rate now stands at -9.88%.
  • The 2 year revenue growth rate now stands at 4.11%.
BMRN's revenue has moved up $512,008,000 over the prior 49 months.

The table below shows BMRN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 2,008.311 180.296 83.912
2022-06-30 1,911.709 119.035 54.07
2022-03-31 1,879.604 145.593 39.347
2021-12-31 1,846.275 304.536 -64.08
2021-09-30 1,848.582 279.972 15.917
2021-06-30 1,916.624 269.118 837.214

BMRN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BMRN has a Quality Grade of C, ranking ahead of 36.95% of graded US stocks.
  • BMRN's asset turnover comes in at 0.314 -- ranking 144th of 682 Pharmaceutical Products stocks.
  • APVO, IRWD, and AVEO are the stocks whose asset turnover ratios are most correlated with BMRN.

The table below shows BMRN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.314 0.742 -0.006
2021-06-30 0.323 0.707 -0.008
2021-03-31 0.319 0.711 -0.019
2020-12-31 0.338 0.718 -0.003
2020-09-30 0.357 0.735 0.005
2020-06-30 0.383 0.782 0.022

BMRN Price Target

For more insight on analysts targets of BMRN, see our BMRN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $110.83 Average Broker Recommendation 1.4 (Moderate Buy)

BMRN Stock Price Chart Interactive Chart >

Price chart for BMRN

BMRN Price/Volume Stats

Current price $116.71 52-week high $117.77
Prev. close $115.35 52-week low $70.73
Day low $114.25 Volume 1,576,100
Day high $116.86 Avg. volume 1,690,438
50-day MA $106.09 Dividend yield N/A
200-day MA $90.36 Market Cap 21.65B

BioMarin Pharmaceutical Inc (BMRN) Company Bio


BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United StatesSouth AmericaAsia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU). (Source:Wikipedia)


BMRN Latest News Stream


Event/Time News Detail
Loading, please wait...

BMRN Latest Social Stream


Loading social stream, please wait...

View Full BMRN Social Stream

Latest BMRN News From Around the Web

Below are the latest news stories about BIOMARIN PHARMACEUTICAL INC that investors may wish to consider to help them evaluate BMRN as an investment opportunity.

Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last?

Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Yahoo | January 25, 2023

3 Drug Stocks With Promising Pipelines for 2023

These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors.

Alex Sirois on InvestorPlace | January 23, 2023

Cramer Is Holding This Biotech Stock

On CNBC’s "Mad Money Lightning Round," Jim Cra mer recommended holding Biomarin Pharmaceutical Inc (NASDAQ: BMRN ). When asked about Black Stone Minerals LP (NYSE: BSM ), he said, "I like this situation." Don’t forget to check out our premarket coverage here . "That’s … Full story available on Benzinga.com

Benzinga | January 12, 2023

Cramer''s lightning round: I would hold onto Biomarin Pharmaceutical

"Mad Money" host Jim Cramer rings the lightning round bell, which means he''s giving his answers to callers'' stock questions at rapid speed.

CNBC | January 11, 2023

2 Top Biotech Stocks Defying the Bear Market

The SPDR S&P Biotech ETF is down 20% over the past year. In fact, BioMarin Pharmaceuticals (NASDAQ: BMRN) and Novo Nordisk (NYSE: NVO) are at their highest levels in a year. The company was founded in 1997 to develop treatments for extremely rare genetic diseases.

Yahoo | January 10, 2023

Read More 'BMRN' Stories Here

BMRN Price Returns

1-mo 16.00%
3-mo 41.48%
6-mo 21.80%
1-year 31.97%
3-year 38.92%
5-year 28.51%
YTD 12.77%
2022 17.14%
2021 0.75%
2020 3.71%
2019 -0.70%
2018 -4.51%

Continue Researching BMRN

Here are a few links from around the web to help you further your research on Biomarin Pharmaceutical Inc's stock as an investment opportunity:

Biomarin Pharmaceutical Inc (BMRN) Stock Price | Nasdaq
Biomarin Pharmaceutical Inc (BMRN) Stock Quote, History and News - Yahoo Finance
Biomarin Pharmaceutical Inc (BMRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7568 seconds.